Plant Name: Glycyrrhiza glabra
Taxonomic Information:
Plant ID: NPO29384
Plant Latin Name: Glycyrrhiza glabra
Taxonomy Genus: Glycyrrhiza
Taxonomy Family: Fabaceae
Plant External Links:
NCBI TaxonomyDB:
49827
Plant-of-the-World-Online:
n.a.
Used in Medicines:
Country/Region:
Turkey; Afghanistan; Madagascar; Italy; Turkmenistan; India; France; Swaziland; Israel; Zimbabwe; Jordan; Thailand; Iraq; Spain; Indonesia; United States; Russia; Bulgaria; Pakistan; Angola; South Africa; Lebanon; China; South KoreaTraditional Medicine System:
Sowa-Rigpa; Indian Folk; Unani; Siddha; Ayurveda; TCMMedicinal Functions:
Alterative; Antiinflammatory; Antispasmodic; Demulcent; Diuretic; Emollient; Expectorant; Laxative; Miscellany; Pectoral; Tonic
Geographical Distribution:
Turkey; Afghanistan; Madagascar; Italy; Turkmenistan; India; France; Swaziland; Israel; Zimbabwe; Jordan; China; Iraq; Spain; Indonesia; United States; Thailand; Russia; Bulgaria; Pakistan; Angola; South Africa; Lebanon; South Korea
Example Image
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; | |
| PTPN1; CDC25B; | |
| ACHE; | |
| BLM; HSD11B1; HSD11B2; AKR1B1; USP2; BRCA1; TNKS; TNKS2; AOX1; | |
| MAPK1; EGFR; | |
| CA2; CA12; CA14; CA7; CA4; | |
| ESR2; ESR1; | |
| NR1H4; | |
| ESRRB; ESRRA; | |
| TYR; ALDH2; | |
| KDM4E; | |
| CASP1; CASP7; | |
| TP53; | |
| KMT2A; | |
| SLCO1B3; SLCO1B1; | |
| HTT; RAB9A; NPC1; LMNA; HBB; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cysteine protease | CASP1 | Caspase-1 | P29466 | CHEMBL4801 |
| Cysteine protease | CASP7 | Caspase-7 | P55210 | CHEMBL3468 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | HSD11B1 | 11-beta-hydroxysteroid dehydrogenase 1 | P28845 | CHEMBL4235 |
| Enzyme_unclassified | HSD11B2 | 11-beta-hydroxysteroid dehydrogenase 2 | P80365 | CHEMBL3746 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| Enzyme_unclassified | BRCA1 | Breast cancer type 1 susceptibility protein | P38398 | CHEMBL5990 |
| Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
| Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
| Enzyme_unclassified | AOX1 | Aldehyde oxidase | Q06278 | CHEMBL3257 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Nuclear hormone receptor subfamily 3 group B | ESRRB | Estrogen-related receptor beta | O95718 | CHEMBL3751 |
| Nuclear hormone receptor subfamily 3 group B | ESRRA | Estrogen-related receptor alpha | P11474 | CHEMBL3429 |
| Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
| Oxidoreductase | ALDH2 | Aldehyde dehydrogenase | P05091 | CHEMBL1935 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Plant homeodomain | KMT2A | Histone-lysine N-methyltransferase MLL | Q03164 | CHEMBL1293299 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
| Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
| Protein Phosphatase | CDC25B | Dual specificity phosphatase Cdc25B | P30305 | CHEMBL4804 |
| SLC superfamily of solute carriers | SLCO1B3 | Solute carrier organic anion transporter family member 1B3 | Q9NPD5 | CHEMBL1743121 |
| SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | HBB | Hemoglobin beta chain | P68871 | CHEMBL4331 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.432E-10 | 6.487E-07 | CA12, CA14, CA2, CA4, CA7 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.489E-10 | 6.487E-07 | BLM, BRCA1, CA12, CA2, CA4, CA7, ESR1, ESR2, ESRRA, ESRRB, KMT2A, NR1H4, PTPN1, TNKS, TP53 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 6.483E-10 | 2.323E-06 | CA12, CA14, CA2, CA4, CA7, HBB |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 7.468E-10 | 2.323E-06 | CYP19A1, CYP1A1, CYP1B1, CYP2C19, CYP2C9, HBB |
| MF | GO:0005488; binding | GO:0005496; steroid binding | 9.068E-10 | 2.468E-06 | ESR1, ESR2, ESRRA, ESRRB, HSD11B2, NPC1, NR1H4 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 4.868E-09 | 7.362E-06 | CYP1A1, CYP1B1, CYP2C19, CYP2C9 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 6.948E-08 | 5.604E-05 | AOX1, CYP19A1, CYP1A1, CYP1B1, CYP2C19, CYP2C9, HBB |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 7.893E-08 | 5.843E-05 | BLM, BRCA1, CASP7, CYP1A1, CYP1B1, EGFR, ESR1, MAPK1, NPC1 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.362E-07 | 8.475E-05 | CYP1A1, CYP1B1, CYP2C19, CYP2C9 |
| BP | GO:0050896; response to stimulus | GO:0071417; cellular response to organonitrogen compound | 2.150E-07 | 1.177E-04 | AKR1B1, BLM, BRCA1, CASP7, EGFR, MAPK1, NR1H4, TP53, TSHR |
| MF | GO:0005488; binding | GO:0020037; heme binding | 4.322E-07 | 1.961E-04 | CYP19A1, CYP1A1, CYP1B1, CYP2C19, CYP2C9, HBB |
| BP | GO:0050896; response to stimulus | GO:0033993; response to lipid | 4.582E-07 | 2.036E-04 | CA2, CASP1, CYP1A1, EGFR, ESR1, ESRRA, HSD11B2, NPC1, NR1H4, TP53, TYR |
| BP | GO:0009987; cellular process | GO:0043401; steroid hormone mediated signaling pathway | 4.736E-07 | 2.063E-04 | BRCA1, ESR1, ESR2, ESRRA, ESRRB, NR1H4 |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 1.033E-06 | 3.946E-04 | CYP19A1, CYP1A1, CYP2C19, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.308E-06 | 4.825E-04 | CA12, CA2, CA4, CA7 |
| BP | GO:0009987; cellular process | GO:0030522; intracellular receptor signaling pathway | 2.693E-06 | 9.307E-04 | BRCA1, ESR1, ESR2, ESRRA, ESRRB, NR1H4 |
| BP | GO:0009987; cellular process | GO:0035690; cellular response to drug | 3.167E-06 | 1.058E-03 | AKR1B1, BLM, BRCA1, CYP1B1, EGFR, MAPK1, TP53 |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 3.830E-06 | 1.191E-03 | CA2, CA4, EGFR, SLCO1B1, SLCO1B3, TSHR |
| BP | GO:0050896; response to stimulus | GO:0034614; cellular response to reactive oxygen species | 4.544E-06 | 1.356E-03 | AKR1B1, CYP1B1, EGFR, MAPK1, TP53 |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 5.071E-06 | 1.434E-03 | ESR1, ESR2 |
| BP | GO:0065007; biological regulation | GO:1904355; positive regulation of telomere capping | 7.333E-06 | 1.857E-03 | MAPK1, TNKS, TNKS2 |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 8.951E-06 | 2.166E-03 | ACHE, AOX1, BLM, CASP1, EGFR, ESR1, ESR2, HTT, KMT2A, MAPK1, RAB9A, TP53, TYR, USP2 |
| CC | GO:0044464; cell part | GO:0048471; perinuclear region of cytoplasm | 1.245E-05 | 2.796E-03 | ACHE, AKR1B1, CA4, EGFR, HTT, NPC1, TNKS2, TYR, USP2 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.519E-05 | 3.375E-03 | CA2, CA7 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.892E-05 | 4.119E-03 | CYP19A1, CYP1A1, CYP1B1 |
| BP | GO:0050896; response to stimulus | GO:0043627; response to estrogen | 2.273E-05 | 4.900E-03 | BRCA1, CA2, ESR1, MAPK1 |
| BP | GO:0008152; metabolic process | GO:0070213; protein auto-ADP-ribosylation | 3.034E-05 | 6.117E-03 | TNKS, TNKS2 |
| MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 3.034E-05 | 6.117E-03 | ESR1, ESR2 |
| BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 3.064E-05 | 6.122E-03 | ESR1, ESR2, ESRRA, ESRRB, NR1H4 |
| BP | GO:0050896; response to stimulus | GO:0033273; response to vitamin | 3.598E-05 | 6.996E-03 | CYP1A1, EGFR, TP53, TYR |
| BP | GO:0008152; metabolic process | GO:2000377; regulation of reactive oxygen species metabolic process | 3.982E-05 | 7.605E-03 | BRCA1, CYP1B1, EGFR, HBB, TP53 |
| BP | GO:0008152; metabolic process | GO:0016579; protein deubiquitination | 4.230E-05 | 7.952E-03 | BRCA1, ESR1, TNKS, TNKS2, TP53, USP2 |
| BP | GO:0051179; localization | GO:0015721; bile acid and bile salt transport | 4.289E-05 | 7.952E-03 | NR1H4, SLCO1B1, SLCO1B3 |
| BP | GO:0008152; metabolic process | GO:0042743; hydrogen peroxide metabolic process | 4.289E-05 | 7.952E-03 | CYP1A1, EGFR, HBB |
| BP | GO:0008152; metabolic process | GO:0045893; positive regulation of transcription, DNA-templated | 5.306E-05 | 9.382E-03 | BLM, BRCA1, EGFR, ESR1, ESR2, ESRRA, ESRRB, KMT2A, MAPK1, NR1H4, TNKS, TP53 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 2.473E-10 | 3.833E-08 | CA12, CA2, CA4, CA7, CA14 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 1.713E-07 | 1.327E-05 | HSD11B1, HSD11B2, CYP1A1, CYP1B1, CYP19A1 |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 1.757E-06 | 6.809E-05 | ALDH2, CYP1A1, AOX1, CYP1B1 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 9.809E-07 | 5.068E-05 | HSD11B1, CYP2C9, CYP1A1, CYP1B1, CYP2C19 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 1.985E-05 | 5.129E-04 | HSD11B1, CYP2C9, CYP1A1, CYP1B1 |
| 09150 Organismal Systems | 09154 Digestive system | hsa04976 | Bile secretion | 1.778E-05 | 5.129E-04 | SLCO1B1, CA2, SLCO1B3, NR1H4 |
| 09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 4.478E-05 | 9.915E-04 | CYP1B1, MAPK1, BRCA1, TP53, EGFR, CDC25B |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 6.587E-05 | 1.276E-03 | MAPK1, ESR1, EGFR, ESR2 |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 2.512E-04 | 3.027E-03 | CASP7, LMNA, MAPK1, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 9.989E-05 | 1.720E-03 | MAPK1, TP53, EGFR |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 1.811E-04 | 2.808E-03 | CYP1A1, CYP1B1, CYP19A1 |
| 09160 Human Diseases | 09161 Cancers | hsa05213 | Endometrial cancer | 2.036E-04 | 2.869E-03 | MAPK1, TP53, EGFR |
| 09160 Human Diseases | 09161 Cancers | hsa05223 | Non-small cell lung cancer | 2.538E-04 | 3.027E-03 | MAPK1, TP53, EGFR |
| 09160 Human Diseases | 09161 Cancers | hsa05214 | Glioma | 3.945E-04 | 3.933E-03 | MAPK1, TP53, EGFR |
| 09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 4.127E-04 | 3.933E-03 | MAPK1, TP53, EGFR |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 3.945E-04 | 3.933E-03 | CYP2C9, CYP1A1, AOX1 |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 4.314E-04 | 3.933E-03 | MAPK1, TP53, EGFR |
| 09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 5.115E-04 | 4.130E-03 | MAPK1, TP53, EGFR |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 5.329E-04 | 4.130E-03 | MAPK1, ESR1, ESR2 |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 1.018E-03 | 6.575E-03 | MAPK1, TP53, ESR1, EGFR |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 4.703E-04 | 4.050E-03 | CYP2C9, AOX1, CYP2C19 |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 1.290E-03 | 7.687E-03 | HSD11B1, CYP2C9, ALDH2, CYP1A1, AKR1B1, AOX1, CYP2C19, TYR, CYP19A1 |
| 09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 9.887E-04 | 6.575E-03 | MAPK1, TP53, EGFR |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 5.775E-04 | 4.232E-03 | PTPN1, MAPK1, EGFR |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05133 | Pertussis | 6.006E-04 | 4.232E-03 | CASP7, CASP1, MAPK1 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 1.916E-03 | 9.898E-03 | CYP2C9, MAPK1, CYP2C19 |
| 09160 Human Diseases | 09161 Cancers | hsa05216 | Thyroid cancer | 1.849E-03 | 9.884E-03 | MAPK1, TP53 |
| Unclassified | Unclassified | hsa04320 | Dorso-ventral axis formation | 1.603E-03 | 9.204E-03 | MAPK1, EGFR |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 1.849E-03 | 9.884E-03 | CYP2C9, CYP2C19 |
| 09150 Organismal Systems | 09155 Excretory system | hsa04964 | Proximal tubule bicarbonate reclamation | 1.162E-03 | 7.205E-03 | CA2, CA4 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
| C00-D49: Neoplasms | Prostate cancer | C61 | ESR1; EGFR; |
| C00-D49: Neoplasms | Breast cancer | C50 | ESR1; EGFR; CYP19A1; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | ALDH2; |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53; |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | HSD11B1; HSD11B2; PTPN1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MAPK1; EGFR; TP53; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | EGFR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | HSD11B1; PTPN1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | HSD11B1; ESRRA; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | EGFR; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | EGFR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
| J00-J99: Diseases of the respiratory system | Influenza virus | J11.1 | HSD11B1; |
| C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| C00-D49: Neoplasms | Urethral cancer | NA | EGFR; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR; |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | CASP1; |
| NA: NA | Gonorrheal vaginitis | NA | ESR1; |
| C00-D49: Neoplasms | Glioma | C71 | EGFR; |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1; EGFR; |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | EGFR; |
| C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR; |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | EGFR; |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1; |
| NA: NA | Edema | NA | CA2; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | ESRRA; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | HSD11B1; |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53; |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | RAB9A; |
| C00-D49: Neoplasms | Gastric cancer | C16 | EGFR; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | ESRRA; CASP1; AKR1B1; TYR; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | EGFR; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR; |
| A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
| NA: NA | Postmenopausal disorder | NA | ESR1; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | ESR1; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | EGFR; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ESR1; ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
| C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR; |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1; ESRRA; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | EGFR; AKR1B1; TP53; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; HSD11B1; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; CA2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | HSD11B1; |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1; |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1; |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1; |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1; |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1; |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | ESRRA; EGFR; |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
| H00-H59: Diseases of the eye and adnexa | Choroidal neovascularisation | H35 | ESRRA; |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1; |
| C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR; |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ESRRA; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ESRRA; |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | HSD11B1; |
| C00-D49: Neoplasms | Colon cancer | C50 | EGFR; |
| NA: NA | Colour dead tissues | NA | PTPN1; |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | ALDH2; |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1; |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR; |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | CASP1; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | EGFR; TP53; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | ESRRA; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | HSD11B1; PTPN1; AKR1B1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | EGFR; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; AKR1B1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1; |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ALDH2; EGFR; |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1; |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1; |
| NA: NA | Menopausal disorder | NA | ESR1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR; |
| C00-D49: Neoplasms | Melanoma | C43 | EGFR; TYR; |
| C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR; |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53; |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1; |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1; |
| C00-D49: Neoplasms | Cancer | C00-C96 | ESR1; ACHE; MAPK1; EGFR; TP53; CDC25B; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | ESRRA; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1; |
| C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | EGFR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ESRRA; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Beta thalassemia | D56.1 | HBB; |
| C00-D49: Neoplasms | Bladder cancer | C67 | EGFR; CYP19A1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic syndrome x | E88.81 | HSD11B1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | HSD11B1; |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ESRRA; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
